Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

About this update from Celcuity Inc.

[{"type":"image","alt":"Celcuity Inc.","displaySize":"","headline":null,"caption":"Celcuity Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/0f5ff122ae01812e1c96be03e8598b65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aT0CeGgbDCIqj5AUGMKkCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/0f5ff122ae01812e1c96be03e8598b65","width":300,"height":85},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/aT0CeGgbDCIqj5AUGMKkCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/0f5ff122ae01812e1c96be03e8598b65","width":300,"height":85}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2026 after the market closes on Thursday, May 14, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.","length":448,"tagName":"p"},{"type":"text","content":"Webcast and Conference Call Information","length":39,"tagName":"p"},{"type":"text","content":"To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1760785&tp_key=2f73ec65ba. A replay of the webcast will be available on the Celcuity website following the live event.","length":377,"tagName":"p"},{"type":"text","content":"About Celcuity","length":14,"tagName":"p"},{"type":"text","content":"Celcuity is a clinical-stage biotechnology company pursuing the development of targeted therapies for the treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIK...

More updates from Celcuity Inc.